Business
Ipsen nominates Peter Guenter to its Board of Directors
Ipsen Board of Directors Peter Guenter Ipsen announced the co-optation of Peter Guenter to its Board as a Director, effective January 28, 2026. PARIS, FRANCE, 29 January 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the co-optation of Peter Guenter to its Board as a Director, effective January 28, 2026, further to the vacancy of Mr. Henri Beaufour’s position. Peter Guenter holds nearly 40 years of experience as an executive leader in the global pharmaceutical industry. Most recently,
About this update from Ipsen Sa
[{"type":"image","alt":"Ipsen Pharma","displaySize":"","headline":null,"caption":"Ipsen Pharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/e6eb628cc0e353381e6b738c556a0e31"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/89RavcsKEHEdDt270X336Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e6eb628cc0e353381e6b738c556a0e31","width":300,"height":157}},"lazy":false},{"type":"text","content":"Ipsen Board of Directors Peter Guenter","length":38,"tagName":"p"},{"type":"image","alt":"Ipsen announced the co-optation of Peter Guenter to its Board as a Director, effective January 28, 2026.","displaySize":"","headline":null,"caption":"Ipsen announced the co-optation of Peter Guenter to its Board as a Director, effective January 28, 2026.","credit":"GlobeNewswire Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":1143,"height":1061,"url":"https://media.zenfs.com/en/globenewswire.com/34fbb42d572f33d4ebfce872066a8980"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5gu_.wQF_fFnKyKmDoK8zA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTg5MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/34fbb42d572f33d4ebfce872066a8980","width":960,"height":891},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/9QqGhKKhusdLmWeS6Qk2Pg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIyODY7aD0yMTIyO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/34fbb42d572f33d4ebfce872066a8980","width":1143,"height":1061}}},{"type":"text","content":"PARIS, FRANCE, 29 January 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the co-optation of Peter Guenter to its Board as a Director, effective January 28, 2026, further to the vacancy of Mr. Henri Beaufour’s position.","length":233,"tagName":"p"},{"type":"text","content":"Peter Guenter holds nearly 40 years of experience as an executive leader in the global pharmaceutical industry. Most recently, he served as Chief Executive Officer of Merck Healthcare and member of the Executive Board of Merck Group from 2021 to 2025. Prior to that, Peter was CEO at Almirall, where from 2017 onward, he led the company’s strategic refocus on medical dermatology. He also spent more than 20 years at Sanofi across numerous leadership roles and joined Sanofi's Executive Committee in 2013.","len...